Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 5/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056454 | 0.85 | TBK1 (0.55) | TBK1AURKASCDNPBWR1ATR | |
| SCHEMBL4054040 | 0.81 | AURKA (0.60) | TBK1AURKANPBWR1SMN1; SMN2 | |
| SCHEMBL13607864 | 0.81 | TBK1 (0.55) | TBK1SCDNPBWR1ATRALOX5 | |
| SCHEMBL4059279 | 0.80 | TBK1 (0.50) | TBK1AURKASCDNPBWR1ATR | |
| SCHEMBL1667430 | 0.79 | AURKA (0.68) | AURKASMN1; SMN2KITMEN1KMT2A | |
| SCHEMBL4050208 | 0.79 | AURKA (0.76) | AURKASMN1; SMN2 | |
| SCHEMBL4058129 | 0.78 | AURKA (0.56) | AURKASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4058364 | 0.78 | AURKA (0.56) | AURKANPBWR1SMN1; SMN2 | |
| SCHEMBL4051632 | 0.78 | SCD (0.53) | TBK1AURKASCDNPBWR1ATR | |
| SCHEMBL4057871 | 0.78 | AURKA (0.56) | AURKASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | TBK1 1212/4885AURKA 247/4885SCD 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.